Welcome to our dedicated page for Benitec Biopharma news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharma stock.
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company pioneering the use of its proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform to develop novel genetic medicines. Headquartered in Hayward, California, Benitec is focused on creating treatments for chronic and life-threatening human diseases through gene-silencing technology that targets and 'turns off' specific disease-related genes, offering sustained treatments, and even potential cures, with a single dose.
Benitec's ddRNAi technology combines RNA interference with gene therapy to deliver long-lasting silencing of disease-causing genes. This approach has significant advantages over traditional RNA interference methods, being easier to deliver, safer, more targeted, and more efficient. This transformative technology is protected by over 40 global patents and can potentially silence genes related to thousands of human diseases.
The company is advancing a robust pipeline of in-house and partnered drug development programs targeting conditions such as Oculopharyngeal Muscular Dystrophy (OPMD) and Hepatitis B Virus (HBV). One of its leading projects, BB-301, is designed to slow or halt the progression of OPMD by silencing the faulty mutant PABPN1 gene and replacing it with a functional version. The BB-301 program has shown promising preliminary results, with significant improvements in clinical trial endpoints.
Benitec has recently announced several operational updates, including the initiation of the first clinical trial using the 'Silence and Replace' platform and the successful closing of a $40 million PIPE financing to support the development and commercialization of BB-301. The company's financial condition shows a focused investment in research and development with notable participation from prominent investors.
For the latest updates on Benitec Biopharma's performance, projects, and developments, visit their official website at www.benitec.com.
Benitec Biopharma (NASDAQ: BNTC) reported its financial results for the second fiscal quarter ending December 31, 2022. Revenue decreased to $14,000 from $25,000 year-over-year, while operating expenses rose to $5.6 million. Research and development expenses specifically for its OPMD project increased to $3.8 million. Notably, the first patient has been enrolled in the BB-301 clinical development program aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD). The company anticipates interim clinical results in 2023 following a six-month observational study and subsequent dosing of BB-301.
Benitec Biopharma Inc. (NASDAQ: BNTC) has announced the enrollment of its first patient into the natural history phase of its BB-301 clinical development program targeted at oculopharyngeal muscular dystrophy (OPMD). This six-month pre-treatment observation phase aims to evaluate baseline patient conditions before proceeding with the Phase 1b/2a treatment study scheduled for 2023. CEO Jerel A. Banks stated that high enrollment interest has been reported, marking a significant milestone for the Company's clinical development goals. The NH Study will utilize various quantitative radiographic measures to assess dysphagia progression in OPMD patients.
Benitec Biopharma Inc. (NASDAQ: BNTC) announced its Fiscal Year First Quarter financial results for the period ending September 30, 2022. The company reported a net loss of $5.1 million, or $0.47 per share, an improvement from a net loss of $5.0 million, or $0.62 per share, in the same quarter last year. Total revenues remained at $0. Total expenses decreased to $4.6 million from $4.8 million. Significant progress was made in the Oculopharyngeal Muscular Dystrophy (OPMD) Natural History Study, with subject screening set to start in November 2022. The company anticipates initiating its BB-301 treatment study in 2023.
FAQ
What is the current stock price of Benitec Biopharma (BNTC)?
What is the market cap of Benitec Biopharma (BNTC)?
What does Benitec Biopharma Inc. specialize in?
What is the 'Silence and Replace' platform?
What diseases is Benitec targeting with its technology?
What is BB-301?
What recent achievements has Benitec Biopharma announced?
How is Benitec's ddRNAi technology different from traditional RNA interference?
How can I learn more about Benitec Biopharma's developments?
What financial condition is Benitec Biopharma in?
Is Benitec Biopharma involved in any partnerships?
What makes Benitec's technology transformative?
